MAIA Earnings — MAIA Biotechnology, Inc. Post-ER Performance | BigEarnings
MAIA — MAIA Biotechnology, Inc.
XASE
Price$1.43
Market Cap$82.1M
P/E—
52W Range$0.87 – $3.19
Next Earnings2026-08-10
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
